NASDAQ:GLYC - GlycoMimetics Stock Price, Forecast & News

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

GlycoMimetics Inc (NASDAQ:GLYC) posted its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.39) by $0.08. View GlycoMimetics' Earnings History.

GlycoMimetics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for GlycoMimetics.

6 Wall Street analysts have issued twelve-month price targets for GlycoMimetics' stock. Their forecasts range from $5.00 to $18.00. On average, they expect GlycoMimetics' share price to reach $9.25 in the next year. This suggests a possible upside of 145.4% from the stock's current price. View Analyst Price Targets for GlycoMimetics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GlycoMimetics.

News stories about GLYC stock have been trending somewhat negative on Wednesday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. GlycoMimetics earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for GlycoMimetics.

Some companies that are related to GlycoMimetics include Phoenix Tree (IMAB), Omeros (OMER), Cara Therapeutics (CARA), G1 Therapeutics (GTHX), Basilea Pharmaceutica (BPMUF), Molecular Templates (MTEM), Vanda Pharmaceuticals (VNDA), Provention Bio (PRVB), RAPT Therapeutics (RAPT), Flexion Therapeutics (FLXN), Emisphere Technologies (EMIS), Urogen Pharma (URGN), Atreca (BCEL), Kadmon (KDMN) and BioXcel Therapeutics (BTAI).

Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), Agile Therapeutics (AGRX), Viking Therapeutics (VKTX), Amarin (AMRN), TG Therapeutics (TGTX), Vanda Pharmaceuticals (VNDA), Fate Therapeutics (FATE), Nabriva Therapeutics (NBRV), Pieris Pharmaceuticals (PIRS) and Amicus Therapeutics (FOLD).

GlycoMimetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include AXA (2.18%), State Street Corp (1.48%), Geode Capital Management LLC (1.13%), Oxford Asset Management LLP (0.31%), Panagora Asset Management Inc. (0.27%) and Bank of New York Mellon Corp (0.26%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Bvf Partners L P/Il, Daniel M Junius, John L Magnani and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.

GLYC stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Alambic Investment Management L.P., State Street Corp, Bank of New York Mellon Corp, Bank of America Corp DE and Geode Capital Management LLC. View Insider Buying and Selling for GlycoMimetics.

GLYC stock was purchased by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Panagora Asset Management Inc., Jacobs Levy Equity Management Inc., California Public Employees Retirement System, Virtus ETF Advisers LLC, UBS Group AG, AXA and AQR Capital Management LLC. Company insiders that have bought GlycoMimetics stock in the last two years include Bvf Partners L P/Il and Daniel M Junius. View Insider Buying and Selling for GlycoMimetics.

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GLYC stock can currently be purchased for approximately $3.77.

GlycoMimetics has a market capitalization of $163.47 million. The biotechnology company earns $-48,270,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe.View Additional Information About GlycoMimetics.

The official website for GlycoMimetics is http://www.glycomimetics.com/.

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]